Abiomed Inc. (NASDAQ:ABMD)’s share price reached a new 52-week high on Wednesday . The company traded as high as $119.90 and last traded at $118.66, with a volume of 476,228 shares traded. The stock had previously closed at $116.59.

ABMD has been the subject of a number of recent research reports. Leerink Swann reiterated a “buy” rating on shares of Abiomed in a report on Sunday, April 17th. Jefferies Group reiterated a “buy” rating on shares of Abiomed in a report on Saturday, April 9th. Zacks Investment Research upgraded shares of Abiomed from a “hold” rating to a “buy” rating and set a $106.00 price objective for the company in a report on Thursday, May 5th. Finally, Benchmark Co. reiterated a “buy” rating and issued a $145.00 price objective on shares of Abiomed in a report on Sunday, April 10th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $111.98.

The company’s 50-day moving average price is $107.45 and its 200 day moving average price is $94.31. The company has a market capitalization of $5.02 billion and a price-to-earnings ratio of 139.11.

Abiomed (NASDAQ:ABMD) last issued its earnings results on Tuesday, May 3rd. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.19 by $0.05. During the same quarter in the previous year, the firm posted $2.24 earnings per share. The firm earned $94 million during the quarter, compared to analyst estimates of $90.52 million. Abiomed’s quarterly revenue was up 39.1% compared to the same quarter last year. On average, equities research analysts forecast that Abiomed Inc. will post $1.13 EPS for the current fiscal year.

In other news, COO David M. Weber sold 52,000 shares of the business’s stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $95.27, for a total value of $4,954,040.00. Following the completion of the transaction, the chief operating officer now directly owns 121,676 shares in the company, valued at approximately $11,592,072.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO David M. Weber sold 2,145 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $93.82, for a total transaction of $201,243.90. Following the completion of the transaction, the chief operating officer now owns 117,411 shares of the company’s stock, valued at $11,015,500.02. The disclosure for this sale can be found here.

Several institutional investors have recently modified their holdings of the stock. KBC Group NV boosted its position in shares of Abiomed by 47.1% in the fourth quarter. KBC Group NV now owns 16,302 shares of the company’s stock valued at $1,472,000 after buying an additional 5,220 shares during the last quarter. Redwood Investments LLC boosted its position in shares of Abiomed by 19.1% in the fourth quarter. Redwood Investments LLC now owns 22,724 shares of the company’s stock valued at $2,052,000 after buying an additional 3,639 shares during the last quarter. Stephens Inc. AR boosted its position in shares of Abiomed by 20.1% in the fourth quarter. Stephens Inc. AR now owns 23,375 shares of the company’s stock valued at $2,110,000 after buying an additional 3,918 shares during the last quarter. State of Tennessee Treasury Department purchased a new position in shares of Abiomed during the fourth quarter valued at approximately $2,726,000. Finally, First Trust Advisors LP boosted its position in shares of Abiomed by 4.2% in the fourth quarter. First Trust Advisors LP now owns 31,747 shares of the company’s stock valued at $2,866,000 after buying an additional 1,275 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.